Medicamen Biotech Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Medicamen Biotech Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 98% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹-174 of operating cash. Lower than 98% of Healthcare companies in India.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 95% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹-174Over the last 3 years, every ₹100 of reported profit came with ₹-174 of operating cash.
Lower than 98% of Healthcare companies in India.
Self-Funding Ratio
-3.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 98% of Healthcare companies in India.
Cash Locked Ratio
₹55For every ₹100 of sales, ₹55 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹45 tied up three years earlier.
More money tied up than 95% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 84% of Healthcare companies in India.
Growth Efficiency Ratio
−₹9Sales grew 40% in 3 years, but profit fell: ₹9 less profit per ₹100 of extra sales.
Lower than 92% of Healthcare companies in India.
Asset Productivity Ratio
+40% / +34%In 3 years sales changed by +40% while total assets changed by +34%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-0.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 95% of Healthcare companies in India.
Cash Cushion Ratio
−5%Debt, after subtracting cash, equals 5% of its market value (net debt).
Lower than 64% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 75% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 78% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Medicamen Biotech Limited owes ₹0.26 for every ₹1 it owns. Net profit rose 36% in the year to Mar 2026, and shrank 13% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
35.8Investors pay ₹35.8 for every ₹1 of Medicamen Biotech Limited's yearly profit, lower than 52% of Healthcare companies in India.
P/B ratio
1.31The share price is 1.31 times Medicamen Biotech Limited's book value per share, lower than 94% of Healthcare companies in India.
Market cap
₹360 CrThe total market value of all of Medicamen Biotech Limited's shares at today's price (share price × number of shares), smaller than 88% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹276 CrWhat Medicamen Biotech Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹203.17Net worth divided by the number of shares. The share price of ₹265.15 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
3.2%Medicamen Biotech Limited earned 3.2% on its shareholders' money over the last year, lower than 86% of Healthcare companies in India.
Owes vs Owns
0.26×Medicamen Biotech Limited owes ₹0.26 for every ₹1 it owns (low), lower than 73% of Healthcare companies in India.
Dividend yield
0.33%Medicamen Biotech Limited pays 0.33% of its share price as dividends a year, lower than 55% of dividend-paying Healthcare companies in India.
Revenue growth
+22%Revenue rose 22% in the year to Mar 2026, and grew 12% a year on average over 3 years.
Profit growth
+36%Net profit rose 36% in the year to Mar 2026, and shrank 13% a year on average over 3 years.
Profit margin
4.9%Medicamen Biotech Limited keeps ₹5 of every ₹100 of revenue as net profit.
Cash quality
-3.4×Cash from Medicamen Biotech Limited's business was -3.4× its reported profit in the year to Mar 2026 — the business used cash even though it reported a profit.
Interest cover
3.5×Medicamen Biotech Limited's operating profit covered its interest costs 3.5 times in the year to Mar 2026.
Cash vs debt
Net debtMedicamen Biotech Limited had ₹17 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Medicamen Biotech Limited's P/E ratio?
Investors pay ₹35.8 for every ₹1 of Medicamen Biotech Limited's yearly profit, lower than 52% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Medicamen Biotech Limited: ₹360 Cr ÷ ₹276 Cr (31 Mar 2026) = 1.3.
What is Medicamen Biotech Limited's return on equity?
Medicamen Biotech Limited earned 3.2% on its shareholders' money over the last year, lower than 86% of Healthcare companies in India.
How much does Medicamen Biotech Limited owe compared with what it owns?
Medicamen Biotech Limited owes ₹0.26 for every ₹1 it owns (low), lower than 73% of Healthcare companies in India.
Does Medicamen Biotech Limited pay a dividend?
Yes. Medicamen Biotech Limited pays 0.33% of its share price as dividends a year, lower than 55% of dividend-paying Healthcare companies in India.
Is Medicamen Biotech Limited's revenue growing?
Revenue rose 22% in the year to Mar 2026, and grew 12% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.